ZX-29

ZX-29 is a potent and selective ALK inhibitor with an IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively. ZX-29 is inactive against EGFR. ZX-29 induces apoptosis by inducing endoplasmic reticulum (ER) stress and overcomes cell resistance caused by an ALK mutation. ZX-29 also induces protective autophagy and has antitumor effect[1].

Product Specifications

CAS Number

[2254805-62-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Anaplastic lymphoma kinase (ALK) ; Apoptosis; Autophagy

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zx-29.html

Purity

98.59

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CS(=O)(NC1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3OC)=NC=C2Cl)=O

Molecular Formula

C23H28ClN7O3S

Molecular Weight

518.03

Precautions

H302, H315, H319

References & Citations

[1]Gou W, et al. ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation. Biochim Biophys Acta Mol Cell Res. 2020 Mar 26;1867 (7) :118712.